Thalidomide for Patients With Mild to Moderate Alzheimer's Disease

Summary

This is a 24-week, randomized, double-blind, placebo-controlled study of the effect of thalidomide and placebo on CSF (cerebral spinal fluid) and plasma biomarkers in patients with mild to moderate Alzheimer's disease. This study will evaluate the effects of 24 weeks of treatment with Thalidomide on plasma biomarkers.

Timeline

Start

2010-03

Primary completion

2012-12

Completion

2013-01

Drugs

Indications